Kangzhe Pharmaceutical (00867): The application for marketing licensing of the innovative drug rucotinib phosphate cream in Singapore was approved

According to Zhitong Financial App, Kangzhe Pharmaceutical (00867) announced that RxilientMedical, a subsidiary of the group, obtained approval from the Singapore Health Sciences Authority (HSA) on November 3, 2026 for the marketing license application (NDA) for lucotinib phosphate cream (“product” or “Lumirix®”) (vitiligo indications). The product is used to treat non-segmental vitiligo in adolescents and adults aged 12 and above with facial involvement. It is the first and only topical prescription drug directly targeting the pathophysiological mechanism of vitiligo in Singapore to meet clinical needs that have not been met for a long time.

This approval has filled a gap in the field of vitiligo treatment in Singapore. In addition to Singapore, up to now, Rxilient Medical has promoted the official launch of sales of Lumirix® (Vitiligo Indication) in the Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan.

Kangzhe Pharmaceutical launched an “industrial internationalization” strategy in 2022, using Singapore as a business hub for emerging markets to establish a closed loop of value for efficient collaboration throughout the “research, production and marketing” industry chain. RxilientMedical is a commercial subsidiary of the Group entering emerging markets. With “global localization” as its core strategy, it is committed to bringing innovative global therapies into emerging markets and benefiting local patients by covering the entire chain of commercialization capabilities covering drug introduction, development, registration, marketing and promotion.